CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy

Author(s): Man-Yu Chu, He-Cheng Huang, En-Ming Li, Li-Yan Xu*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 19 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Cyclophilin A (CypA) is a ubiquitous and highly conserved protein. CypA, the intracellular target protein for the immunosuppressant cyclosporine A (CsA), plays important cellular roles through peptidyl-prolyl cis-trans isomerase (PPIase). Increasing evidence shows that CypA is up-regulated in a variety of human cancers. In addition to being involved in the occurrence and development of multiple tumors, overexpression of CypA has also been shown to be strongly associated with malignant transformation. Surgery, chemotherapy and radiotherapy are the three main treatments for cancer. Chemotherapy and radiotherapy are often used as direct or adjuvant treatments for cancer. However, various side effects and resistance to both chemotherapy and radiotherapy bring great challenges to these two forms of treatment. According to recent reports, CypA can improve the chemosensitivity and/or radiosensitivity of cancers, possibly by affecting the expression of drug-resistant related proteins, cell cycle arrest and activation of the mitogen-activated protein kinase (MAPK) signaling pathways. In this review, we focus on the role of CypA in cancer, its impact on cancer chemotherapeutic and radiotherapy sensitivity, and the mechanism of action. It is suggested that CypA may be a novel potential therapeutic target for cancer chemotherapy and/or radiotherapy.

Keywords: Cancer, cyclophilin A, CD147, CsA, signal transduction, chemotherapy, radiotherapy, therapy target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 29 October, 2020
Page: [3787 - 3802]
Pages: 16
DOI: 10.2174/0929867327666201029161055
Price: $65

Article Metrics

PDF: 216